Jade Biosciences (JBIO) Profit After Tax (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Profit After Tax data on file, last reported at -$40.4 million in Q1 2026.

• Quarterly Profit After Tax fell 5.76% year-over-year to -$40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.4 million (down 2.56% YoY) and the FY2025 annual result came in at -$127.3 million, down 82.46% from the prior year.
• Profit After Tax retreated to -$40.4 million in Q1 2026, from -$31.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$11.5 million in Q1 2022 to a low of -$47.0 million in Q4 2024.
• A 5-year average of -$23.9 million and a median of -$20.0 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 313.34% — and 2025, when it soared 32.3%.
• Tracing JBIO's Profit After Tax over 5 years: stood at -$14.7 million in 2022, then plunged by 35.58% to -$20.0 million in 2023, then sank by 135.45% to -$47.0 million in 2024, then soared by 32.3% to -$31.8 million in 2025, then retreated by 26.93% to -$40.4 million in 2026.
• The last three Profit After Tax figures came in at -$40.4 million (Q1 2026), -$31.8 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.